Creating new mouse models to find treatments for cognitive issues in Down syndrome
Generation and analysis of new mouse models to determine novel therapeutic targets for Down syndrome-associated cognitive deficits
['FUNDING_R01'] · ROSWELL PARK CANCER INSTITUTE CORP · NIH-10908377
This study is looking at how an extra chromosome 21 impacts thinking and learning in people with Down syndrome, using special mouse models to find out which genes might be involved, with the hope of discovering new ways to help improve cognitive abilities for those with the condition.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ROSWELL PARK CANCER INSTITUTE CORP (nih funded) |
| Locations | 1 site (BUFFALO, UNITED STATES) |
| Trial ID | NIH-10908377 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how an extra copy of chromosome 21 affects cognitive development in individuals with Down syndrome. By creating and analyzing new mouse models that mimic this genetic condition, researchers aim to identify specific genes that contribute to cognitive deficits. The study employs advanced genetic techniques, including CRISPR, to explore the relationship between gene dosage and cognitive function. This approach could lead to the discovery of novel therapeutic targets that may improve cognitive outcomes for individuals with Down syndrome.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with Down syndrome, particularly those experiencing cognitive deficits.
Not a fit: Patients without Down syndrome or those who do not exhibit cognitive challenges related to the condition may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly enhance cognitive abilities in individuals with Down syndrome.
How similar studies have performed: Previous research using similar genetic approaches in animal models has shown promise in identifying therapeutic targets for genetic conditions, suggesting a potential for success in this study.
Where this research is happening
BUFFALO, UNITED STATES
- ROSWELL PARK CANCER INSTITUTE CORP — BUFFALO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: YU, EUGENE — ROSWELL PARK CANCER INSTITUTE CORP
- Study coordinator: YU, EUGENE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Bartholin-Patau syndrome, Candidate Disease Gene